Raymond James & Associates grew its stake in shares of Balchem Co. (NASDAQ:BCPC – Get Rating) by 3.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,489 shares of the basic materials company's stock after purchasing an additional 1,261 shares during the period. Raymond James & Associates' holdings in Balchem were worth $5,398,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Conestoga Capital Advisors LLC boosted its stake in Balchem by 1.1% during the first quarter. Conestoga Capital Advisors LLC now owns 1,011,373 shares of the basic materials company's stock worth $138,255,000 after acquiring an additional 10,665 shares in the last quarter. State Street Corp raised its holdings in shares of Balchem by 1.6% during the fourth quarter. State Street Corp now owns 1,004,812 shares of the basic materials company's stock valued at $170,051,000 after purchasing an additional 15,797 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Balchem by 8.1% during the fourth quarter. Geode Capital Management LLC now owns 603,823 shares of the basic materials company's stock valued at $101,804,000 after purchasing an additional 45,326 shares during the last quarter. Schroder Investment Management Group grew its position in Balchem by 3.3% during the fourth quarter. Schroder Investment Management Group now owns 603,136 shares of the basic materials company's stock valued at $101,689,000 after buying an additional 19,063 shares during the period. Finally, Stephens Investment Management Group LLC grew its position in Balchem by 1.4% during the first quarter. Stephens Investment Management Group LLC now owns 320,085 shares of the basic materials company's stock valued at $43,756,000 after buying an additional 4,457 shares during the period. Institutional investors own 89.15% of the company's stock.

Balchem Stock Performance

BCPC opened at $129.20 on Tuesday. The firm has a market cap of $4.15 billion, a P/E ratio of 38.68 and a beta of 0.59. Balchem Co. has a 1-year low of $110.15 and a 1-year high of $174.29. The company has a 50 day simple moving average of $131.41 and a two-hundred day simple moving average of $130.21. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.62 and a quick ratio of 1.64.

Insiders Place Their Bets

Analyst Ratings Changes

Several brokerages recently issued reports on BCPC. HC Wainwright boosted their target price on shares of Balchem from $152.00 to $164.00 and gave the company a "buy" rating in a research report on Monday, August 22nd. StockNews.com lowered shares of Balchem from a "buy" rating to a "hold" rating in a research report on Monday, August 1st.

About Balchem

(Get Rating)

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.

Further Reading

• Get a free copy of the StockNews.com research report on Balchem (BCPC)
• MarketBeat Podcast: Stock Market, Bad News is Good News
• Forget Bitcoin, Block's Ecosystems are the Real Growth Drivers
• What Does an Inverted Yield Curve Mean For You?
• SPY vs. QQQ: Which ETF Wins in 2022?
• Could Snap Stock Rebound As Management Restructures?

Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC – Get Rating).

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.